Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $373.71, while the average Wall Street price target sits at $477.25. That leaves the stock roughly 28% below consensus, and Bernstein pegs fair value at $685, implying returns north of 83%.
Intuitive Surgical dominates the robotic-assisted surgery market with its da Vinci surgical system and Ion lung biopsy platform. It has an installed base of 11,710 da Vinci systems worldwide. Wall Street has treated it as a compounder for years, making the current gap between price and target notable.
How A Compounder Lost A Third Of Its Value
ISRG is down 34.02% year to date and 21.17% over the past twelve months. The trigger was a slower guide, not a broken business. Full-year 2026 da Vinci procedure growth was set at 13.5% to 15.5%, a clear deceleration from the roughly 18% pace investors expected.
Tariffs compounded the damage. Instruments and accessories are manufactured in Mexico, endoscopes in Germany, and certain materials come from China. Management embedded a 1.0% revenue drag from tariffs into gross margin guidance and warned further escalation could materially hit results. HSBC downgraded the stock from Buy to Hold and cut its target from $604 to $391. A Class II recall of 11,113 da Vinci SP drapes added noise, and moderation in U.S. elective procedures tied to ACA subsidy expiration finished the decline.
Why The Bulls Are Still On Board
Analysts remain bullish because the underlying business kept beating expectations through the selloff. Q2 2026 non-GAAP EPS came in at $2.80 versus a $2.50 consensus, revenue of $2.89 billion grew 18.5% year over year, marking the fifth consecutive quarterly beat. Non-GAAP gross margin expanded to 70.0% from 67.9%.
The bull thesis rests on the da Vinci 5 upgrade cycle. Placements hit 246 dV5 systems in Q2, and CFO Jamie Samath compared the trajectory to the Xi cycle, which “took about seven years before we got to the peak trade-in volumes.”. Add a growing recurring instruments base, $8.63 billion in cash, and an extended-use instrument program rolling out in 2027. The rating mix shows 7 analysts rate ISRG Strong Buy, 16 Buy, 9 Hold, and just 1 Sell.
Peers Held Up Better
The medtech group softened in 2026, yet ISRG stands alone in drawdown depth. Its two closest scaled robotic peers held up far better, raising whether the market overcorrected on the leader.
Medtronic (NYSE:MDT) trades at $85.92, down just 9.03% YTD. Its Hugo robotic system cleared FDA for general surgery submission, but robotics is a small part of a diversified device portfolio. The Street target of $98.44 implies about 15% upside, with 18 Buys and 12 Holds.
Stryker (NYSE:SYK) sits at $337.43, off only 3.47% YTD after a Q2 beat driven by 9.0% organic growth and Mako robotic orthopedics. Its $381.50 target implies about 13% upside, with 23 Buys against 5 Holds.
The largest analyst-implied upside sits with Intuitive Surgical by a wide margin. Peers offer roughly half the implied return with far smaller drawdowns, suggesting ISRG’s punishment overshot its fundamental deterioration.
What The Tape Says
Intuitive Surgical trades at $373.71 against an average analyst target of $477.25, implying roughly 28% upside from 33 covering analysts. The stock is down 34.02% year to date while the S&P 500 is up 12.71%, a spread of nearly 47 points against a former market darling.
Valuation still reflects that pedigree. Trailing P/E is 42 and forward P/E sits at 34, both premium to the broader medical device group. Bernstein’s $685 Street-high target is the outlier pinning the 83% figure in the headline, but consensus already argues the derating went too far.
The Case For And Against
The bull case holds if the da Vinci 5 trade-in cycle mirrors the Xi ramp, tariff pressure caps near current guidance, and U.S. elective procedure growth stabilizes as ACA subsidy noise fades. In that scenario, the recurring instruments engine compounds, margins hold near 70%, and the stock reprices toward the Street’s $477.25 average within 12 to 18 months.
The bear case builds if tariffs escalate beyond the current 1.0% drag, Chinese domestic robotic competitors freeze that market, or GLP-1 pressure on bariatric procedures signals broader structural hits to surgical volume. A P/E of 42 leaves no room for error. On balance, the peer comparison makes the drawdown look excessive, but this story needs one more clean quarter before the tape trusts it again.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks